Hepatocellular carcinoma (HCC) remains a global health burden, and is mostly diagnosed
at late and advanced stages. Currently, limited and insensitive diagnostic modalities …

Current anticancer drug research includes tumor-targeted administration as a critical
component because it is the best strategy to boost efficacy and decrease toxicity. Low drug …

Hepatobiliary tumors, which include cholangiocarcinoma, hepatocellular carcinoma (HCC),
and gallbladder cancer, are common cancers that have high morbidity and mortality rates …

Obstructive sleep apnea (OSA) syndrome is characterized by chronic intermittent hypoxia
and is associated with an increased risk of all-cause mortality, including cancer mortality …

Introduction Hepatocellular carcinoma (HCC) is a common solid cancer and the leading
cause of cancer deaths worldwide. Sorafenib is the first drug used to treat HCC but its …

Combining anti‐cancer drugs has been exploited as promising treatment strategy to target
lung cancer. Synergistic chemotherapies increase anti‐cancer effect and reduce effective …

Background Hepatocellular carcinoma (HCC) is the most common neoplasm among primary
liver malignancies, accounting for 70%–85% of total liver cancer cases worldwide. It is also …

Hepatocellular carcinoma (HCC) is the terminal phase of multiple chronic liver diseases,
and evidence supports chronic uncontrollable inflammation being one of the potential …

Herein a practical strategy for augmenting immune activation in transcatheter arterial
chemoembolization (TACE) of hepatocellular carcinoma (HCC) is presented. Pluronic F127 …

Background Nano-based drug delivery systems have shown several advantages in cancer
treatment like specific targeting of cancer cells, good pharmacokinetics, and lesser adverse …